Skip to main content

Table 6 Multivariate analyses (cox regression) of overall survival a in younger and older patients

From: Human BDH2, an anti-apoptosis factor, is a novel poor prognostic factor for de novo cytogenetically normal acute myeloid leukemia

Variables Patients 60 y/o Patients > 60 y/o
  95% CI    95% CI  
HR Lower Upper P HR Lower Upper P
NPM1 b 0.000 0.000 1.490E89 0.898 0.263 0.021 3.377 0.305
FLT3- ITDc 7.505 1.538 36.614 0.013* 3.235 0.424 24.699 0.258
FLT3- TKD 9765.104 32.249 2.95E6 0.002* 144.617 0.000 3.75E169 0.980
CEBPA d 0.357 0.125 1.020 0.054 1.090 0.292 4.066 0.898
IDH1 b 14220.871 0.000 3.9E99 0.932 174.990 0.000 4.56E169 0.979
IDH2 b 0.000 0.000 2.695E210 0.958 0.459 0.050 4.242 0.492
DNMT3A b 146.313 0.000 4.16E97 0.965     
MLL b 0.059 0.000 1.78E94 0.980 2.245 0.173 29.122 0.536
MN1 e 1.923 1.130 3.273 0.016* 1.198 0.916 1.567 0.187
ERG 53.777 1.820 1589.377 0.021* 32.349 2.889 362.237 0.005*
miR-181a 0.514 0.260 1.014 0.055 1.361 0.933 1.986 0.110
miR-3151 1.164 0.580 2.337 0.669 0.423 0.191 0.935 0.033*
BDH2 e 4.829 1.002 23.274 0.050* 18.937 1.571 228.308 0.021*
  1. Abbreviations: HR indicates Hazard ratio; CI, confidence interval.
  2. aOnly patients with intensive induction chemotherapy enrolled.
  3. bNPM1mut versus NPM1wild type; ID H1mut versus IDH1wild type; IDH2mut versus IDH2wild type; DNMT3Amut versus DNMT3Awild type.
  4. cFLT3- ITDmut versus FLT3- ITDneg.
  5. dCEBPAdouble-mutation versus CEBPAsingle mutation versus CEBPAno mutation.
  6. eBDH2high relative to BDH2low group.
  7. *Statistically significant (P < 0.05).